Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Consensus Rating of “Buy” by Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has received a consensus recommendation of “Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a buy rating and three have given a strong buy rating to the company.

Several research firms have issued reports on BAYRY. Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 20th. Morgan Stanley raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Finally, JPMorgan Chase & Co. raised Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th.

Bayer Aktiengesellschaft Trading Up 4.0%

BAYRY opened at $13.65 on Thursday. The stock has a market capitalization of $51.56 billion, a P/E ratio of -151.64, a P/E/G ratio of 4.93 and a beta of 0.66. Bayer Aktiengesellschaft has a 12 month low of $5.30 and a 12 month high of $13.78. The firm’s fifty day simple moving average is $10.57 and its 200 day simple moving average is $8.92. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.